MRKR
Marker Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Dec 8 HC Wainwright & Co. initiates
- Mar 18 Marker Therapeutics reported financial results for 2025, highlightin…
- Mar 19 Marker Therapeutics reported its 2025 financial results and provided…
- Aug 14 ▼ Short interest jumps 29.7% to 200.2K
- Aug 31 ▲ Short interest falls 30.5% to 139.2K
- Sep 15 ▼ Short interest jumps 62.8% to 226.6K
- Sep 30 ▲ Short interest falls 25.5% to 168.9K
- Oct 15 ▲ Short interest falls 35.4% to 109.1K
- Oct 19 Contract: Marker Therapeutics Awarded $2.6 Million FDA Orphan Produc…
- Oct 30 ▼ Short interest jumps 61.4% to 176.1K
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q3 2026: 1 added (0 new), 2 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.185 → −$0.140 over 90 days. 1 up, 0 down in 30 days.
- Short sellersBUILDING
Short interest +61.4% to 176.1K shares. 1.0 days to cover, ≈1.1% of shares.
- TrendDOWNTREND
21% below its 50-day average. New closing low $0.8300 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JANE STREET GROUP, LLC | TRIM | $13.1K |
| UBS Group AG | ADD | $13.0K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $366.7K |
| NORTHERN TRUST CORP | ADD | $50.9K |
| JANE STREET GROUP, LLC | TRIM | $24.7K |
| UBS Group AG | TRIM | $12.0K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $227.9K |
| UBS Group AG | NEAR_EXIT | $42.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Dec 2025Price is below the lowest target. Median implies +864%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Dec 8, 2025 | HC Wainwright & Co. INITIATE | Buy |
| Apr 1, 2025 | WBB Securities REITERATE | Strong Buy |
| Mar 5, 2025 | Canaccord Genuity INITIATE | Buy |
| Apr 30, 2024 | Ladenburg Thalmann INITIATE | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.14 | -$0.16–-$0.12 | +0.0% | $2.1M |
| Next Q | -$0.17 | -$0.22–-$0.12 | +0.0% | $715.3K |
| Current FY | -$0.56 | -$0.63–-$0.50 | +0.0% | $4.2M |
| Next FY | -$0.53 | -$0.89–-$0.17 | +0.0% | $20.2M |
Short side
FINRA· Oct 30, 2026SecBot reports
3 filings · 2 press releases · 1 bullish · 0 bearish · 1 mixed · 1 neutral- BULLISH 8-KOct 19, 2026
Marker Therapeutics announced it was awarded a $2.6 million grant from the FDA's Orphan Products…
The FDA grant provides third-party validation and non-dilutive capital, but the stock impact will depend on Phase 1 data readouts. Monitor for trial initiation in Q1 2027 and any interim efficacy or…
- BULLISH PRESS RELEASEOct 19, 2026
Marker Therapeutics received a $2.6 million FDA Orphan Products Clinical Trials grant to support a…
The grant provides non-dilutive capital and independent validation, but the company remains pre-revenue with no approved products. Monitor for Phase 1 initiation in Q1 2027 and any interim data…
- NEUTRAL DEFA14AMar 20, 2026
Marker Therapeutics is holding its 2026 annual meeting where shareholders will vote on several…
Monitor the shareholder vote outcome, particularly on the share increase proposal, as approval would significantly increase potential dilution. The request to adjourn the meeting suggests management…
- MIXED 8-KMar 19, 2026
Marker Therapeutics reported its 2025 financial results and provided clinical updates…
Monitor upcoming APOLLO study data in Q2 2026 and the initiation of the company-sponsored pancreatic cancer program, which could serve as key catalysts. The reduced R&D spend despite advancing…
All MRKR filing & press-release reports (5)
- 8-K reportOct 19, 2026
- PRESS-RELEASE reportOct 19, 2026
- DEFA14A reportMar 20, 2026
- 8-K reportMar 19, 2026
- PRESS-RELEASE reportMar 18, 2026